CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Cost-Effectiveness of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Hemodialysis Patients
-
5 2011
-
-
Source: Am J Kidney Dis. 2011; 57(5):724-732
[PDF-445.07 KB]
Details:
-
Alternative Title:Am J Kidney Dis
-
Personal Author:
-
Description:Background
Currently, over 340,000 individuals are receiving long-term hemodialysis (HD) therapy for end-stage renal disease and therefore are particularly vulnerable to influenza, prone to more severe influenza outcomes, and less likely to achieve seroprotection from standard influenza vaccines. Influenza vaccine adjuvants, chemical or biological compounds added to a vaccine to boost the elicited immunological response, may help overcome this problem.
Study design
Economic stochastic decision analytic simulation model.
Setting & Participants
United States adult HD population.
Model, Perspective, & Timeframe
The model simulated the decision to use either an adjuvanted or non-adjuvanted vaccine, assumed the societal perspective, and represented a single influenza season, or 1 year.
Intervention
Adjuvanted influenza vaccine at different adjuvant costs and efficacies. Sensitivity analyses explored the impact of varying the influenza clinical attack rate, influenza hospitalization rate, and influenza-related mortality.
Outcomes
Incremental cost-effectiveness ratio (ICER) of adjuvanted influenza vaccine (versus non-adjuvanted) with effectiveness measured in quality-adjusted life-years (QALYs).
Results
Adjuvanted influenza vaccine would be cost-effective (ICER<$50,000/QALY) at a $1 adjuvant cost (on top of the standard vaccine cost) when the adjuvant efficacy (in overcoming the difference between influenza vaccine response in HD patients and healthy adults) ≥60% and economically dominant (provides both cost savings and health benefits) when the $1 adjuvant's efficacy is 100%. A $2 adjuvant would be cost-effective should the adjuvant efficacy be 100%.
Limitations
All models are simplifications of real life and cannot possibly capture all possible factors and outcomes.
Conclusions
An adjuvanted influenza vaccine with adjuvant cost ≤$2 could be cost-effective strategy in a standard influenza season depending on the potency of the adjuvant.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:21396760
-
Pubmed Central ID:PMC3085888
-
Document Type:
-
Funding:
-
Volume:57
-
Issue:5
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
